Use of canps-inhibitors in pharmaceutical preparations

Details Use of canps-inhibitors in pharmaceutical preparations Use of canps-inhibitors in pharmaceutical preparations

A - Human Necessities

61

K

A61K 38/57 (2006.01) A61K 38/55 (2006.01) C07K 14/81 (2006.01)

Patent

CA 2088671

The invention relates to the use of inhibitors of neutral Ca2+ dependent proteinases (CANPs) and their pharmaceutical- ly acceptable addition salts or their active subunits in the field of tumour therapy, especially cancer therapy, viral diseases therapy, AIDS therapy and contraception. The inhibitors can especially be used against protease bound glycosaminoglycan- substrate dependent tumours, viral diseases and contraception by selective malignant cell killing, viruses and spermatozoa killing and inhibiting of nuclear vlimmata in a host-parasite cell system involving common protease bound substrate. The inhibitors are heatstable, tetrameric proteins at neutral pH, approximatively 240 KDa, destroyed with trypsin. The pharma- ceutical compositions may be prepared in a manner known per se, with carriers or additives commonly used in the pharma- ceutical industry.

Affiliated with

Also associated with

Rating

Use of canps-inhibitors in pharmaceutical preparations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of canps-inhibitors in pharmaceutical preparations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of canps-inhibitors in pharmaceutical preparations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1515581